Summary
Background: Fenretinide is a semi-synthetic retinoid that has pro-apoptotic effects as a single agent and synergistically with chemotherapy in vitro. We performed this study to determine the toxicity of cisplatin, paclitaxel and fenretinide in patients with advanced cancer, the recommended phase II dose of these agents together, and the pharmacokinetics (PK) of fenretinide when administered with chemotherapy.
Patients and methods: Fourteen patients (mean age 57.3) were assessable for pharmacokinetics, toxicity and response. Fenretinide was given orally in 2 divided daily doses for 7 days, starting 24 hours prior to cisplatin and paclitaxel. Cisplatin and paclitaxel were given in standard fashion. Cycles were repeated every 3 weeks. Cycle one fenretinide PK was obtained on days 2 and 8.
Results: Dose limiting toxicity (Gr 3 diarrhea and Gr 4 neutropenia) was encountered in two patients during cycle one at 80/175/1800 mg/m2 of cisplatin/paclitaxel/fenretinide (dose level 2), respectively. Seven patients received 2–8 cycles at the recommended level of 60/135/1800 (dose level 1). Severe cumulative toxicities included fatigue, nausea/vomiting, neuropathy, and dehydration. Two patients had a partial response and 4 patients had stable disease for up to 8 cycles. PK analysis demonstrated a reduction in fenretinide Cmax on day 8 compared to day 2, accompanying a decrease in AUC.
Conclusions: Cisplatin/paclitaxel/fenretinide can be administered safely at 60/135/1800 mg/m2 respectively on an every three-week schedule. This combination may have activity in a variety of tumors, however, the number of pills required complicates oral dosing of fenretinide, and limits the applicability of this regimen.
Similar content being viewed by others
References
Lippman SM, Kessler JF, Meyskens FL, Jr.: Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treat Rep 71(4): 391–405, 1987
Naik HR, Kalemkerian G, Pienta KJ: 4-Hydroxyphenylretinamide in the chemoprevention of cancer. Adv Pharmacol 33: 315–347, 1995
Delia D, et al.: N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53(24): 6036–6041, 1993
Mariotti A, et al.: N-(4-hydroxyphenyl)retinamide: A potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 86(16): 1245–1247, 1994
Oridate N, et al.: Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: Implications for chemoprevention. J Cell Biochem Suppl 23: 80–86, 1995
Lotan R.: Retinoids and apoptosis: Implications for cancer chemoprevention and therapy [editorial; comment]. J Natl Cancer Inst 87(22): 1655–1657, 1995
Kalemkerian GP, et al.: Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines [see comments]. J Natl Cancer Inst 87(22): 1674–1680, 1995
Zou CP, et al.: Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 4(5): 1345–1355, 1998
Sun SY, Yue P, Lotan R: Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 55(3): 403–410, 1999
Sun SY, et al.: Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 59(10): 2493–2498, 1999
Maurer BJ, et al.: Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines [see comments]. J Natl Cancer Inst 91(13): 1138–1146, 1999
Cobleigh MA, et al.: Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11(3): 474–477, 1993
Costa A, et al.: Tolerability of the synthetic retinoid Fenretinide (HPR). Eur J Cancer Clin Oncol 25(5): 805–808, 1989
Liebmann JE, et al.: Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6(1): 25–31, 1994
Tolcher AW: Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 23(1 Suppl 1): 37–43, 1996
Kalemkerian GP, Ou X: Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines. Cancer Chemother Pharmacol 43(2): 145–150, 1999
Vaishampayan U, et al.: Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs, 23(2): 179–185, 2005
Puduvalli VK, et al.: Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22(21): 4282–4289, 2004
Therasse P, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comments]. J Natl Cancer Inst 92(3): 205–216, 2000
Doose DR, et al.: Effects of meals and meal composition on the bioavailability of fenretinide. J Clin Pharmacol 32(12): 1089–1095, 1992
Formelli F, et al.: Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11(10): 2036–2042, 1993
Garaventa A, et al.: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9(6): 2032–2039, 2003
Hultin TA, et al.: Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-trans-retinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice. Drug Metab Dispos 16(6): 783–788, 1988
Pitlick WH, et al.: Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 65(3): 462–463, 1976
Conley B, et al.: Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 18(2): 275–283, 2000
Singletary SE, et al.: Phase II clinical trial of N-(4-Hydroxyphenyl) retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8(9): 2835–2842, 2002
Veronesi U, et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer [In Process Citation]. J Natl Cancer Inst 91(21): 1847–1856, 1999
Gupta A, et al.: Effects of dietary N-(4-hydroxyphenyl)retinamide on N-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis in the Fischer 344 rat. J Natl Cancer Inst 93(13): 990–998, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Otterson, G.A., Lavelle, J., Villalona-Calero, M.A. et al. A Phase I Clinical and Pharmacokinetic Study of Fenretinide Combined with Paclitaxel and Cisplatin for Refractory Solid Tumors. Invest New Drugs 23, 555–562 (2005). https://doi.org/10.1007/s10637-005-1665-2
Issue Date:
DOI: https://doi.org/10.1007/s10637-005-1665-2